{"name":"Annovis Bio Inc.","slug":"annovis-bio-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"buntanetap/posiphen","genericName":"buntanetap/posiphen","slug":"buntanetap-posiphen","indication":"Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia stage)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Posiphen","genericName":"Posiphen","slug":"posiphen","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"buntanetap/posiphen","genericName":"buntanetap/posiphen","slug":"buntanetap-posiphen","phase":"phase_3","mechanism":"Buntanetap/posiphen inhibits translation of amyloid precursor protein (APP) and tau, reducing production of amyloid-beta and tau pathology in the brain.","indications":["Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia stage)"],"catalyst":""},{"name":"Posiphen","genericName":"Posiphen","slug":"posiphen","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE4tNTFOcWJucGZyeG4ydkFFZlVCOUdEMTlXaFFGRkdxZzlMUlVFRWZRV25Xc2VEb0NtRGhxN1p2MG9SaUY3TVNGMzFyMmMxeEl6Z3RZRWxYa0F2dw?oc=5","date":"2026-04-01","type":"pipeline","source":"TradingView","summary":"ANVS Stock Price and Chart — NYSE:ANVS - TradingView","headline":"ANVS Stock Price and Chart — NYSE:ANVS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1GRHVtaE44aVE3dnM5NmM2UjNZX3h2NmZXYmNVU25heUQ3VmM1czhfcTZ6TUR1dmJQMC10RzN2aUQtRFl4Mjl0QnR4SFhUWmxGaWZPVlAtUDhVMExRcG1Ka0o4RkI2OXQ0ZFZnb2Zn?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Annovis Bio Inc (ANVS) - Stock Titan","headline":"If You Invested $1,000 in Annovis Bio Inc (ANVS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxON05VaDhJNmVRcE5aQ2gtbi1rY2hDTnhiTko5SExPazgwVk43UzJMN1V1cmt4eVo5enVHNDJjdXhMRnI2ZFd6bjB6cnl6aGtpN2lIUkptbGNvZ0p0N0otRXNLSDlPaGNpc2NWXzhyZVFiNjROOE04c2pFMUdfQlpuUlVzeWFFTzJieXRzZHVfcF9QT1BRek9qZTE1ajFPZ3d6YXdxcGlMSnZGd05TNmZxS0x3dl94YU5BMXhETGR4VnN1VmdJZ2Zz?oc=5","date":"2026-03-01","type":"trial","source":"AD HOC NEWS","summary":"Annovis Bio Stock: Can Fresh Alzheimer’s Data Spark the Next Big Short Squeeze? - AD HOC NEWS","headline":"Annovis Bio Stock: Can Fresh Alzheimer’s Data Spark the Next Big Short Squeeze?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNblpRcElYbjNiNjBtRGdTQ2tjbmlzODlKVEF5OFg2TVBxWUl3S3NhTEQ3V0VHLUN4MTZ0dHp0b3dybnZxQi1MRDJxZG1GWi1NZ2tINy0taTVfRmFEWjhGTnBwWHhQWHA2TUprUENJM01raG4yS0JSX3pSbE1odGNYdDhmclktWFE?oc=5","date":"2025-09-25","type":"pipeline","source":"Yahoo Finance","summary":"Annovis Appoints Mark Guerin as Chief Financial Officer - Yahoo Finance","headline":"Annovis Appoints Mark Guerin as Chief Financial Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxPVkJjQzlFcVZ4YXo5U25MOFYxaTQwcVhGRGhKRElmc1hFS2xMZTZrUlZLNmtoRnJ6MU1jMzdQSnlOVlo2UVdSelRMZ0d6TDBRVkNXazB4bV9tN0IwYzFvalZoNHhxakF3dWQ3eEZNTEtqYms2anBjeWlITWhIbTV3eEszcTFiMi1nSkFkTDBvZXcxa29feUpyOWQzTk5FdExzWFc2TG0wUThVZXp6Sk00T0ozbzhpdjIyQjNLNjFGWmxkejFjZ2xYUmY1aW1acGw5aEVfY29Vcw?oc=5","date":"2025-09-25","type":"pipeline","source":"Quiver Quantitative","summary":"Annovis Bio Appoints Mark Guerin as Chief Financial Officer to Support Late-Stage Development of Buntanetap - Quiver Quantitative","headline":"Annovis Bio Appoints Mark Guerin as Chief Financial Officer to Support Late-Stage Development of Buntanetap","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxNcXJtbk85UXNjZTVHUUhFQlhzWHlOcjVZVENqWUc0c3hMbEs5TXEyeFh3Y0hkZC0teUNiNzBfUlFkbTVZd21LZHd3QmVJMjNPM05UVW0zaEo4SjFBTEdkV2V6cnpuRkYxS01kNzM5TFptSU1Va0JiZFI3cnFRWHBTWkkzUnVRN3paWi1UTW9keUtnaXd1S1NKZ2pyUEhYZ25aVEQzRVFFbW5JR2NjSTdQTWJZcnpoOGZGQ0VSRUR1Nlc0YTNqcVI3MzRfVFhKT1FEaWd0eUx5WXEybDVsM0JUcHIzNGVySnlsMGhPNHZxNFJJVDRlUjQ0REpwREw1Q0VnZjN1eVZKQjRldWFBRW5qdmJOV3Vqd2Mx?oc=5","date":"2025-07-28","type":"pipeline","source":"PR Newswire","summary":"Alpha-synuclein Inhibitors Market to Witness Strong CAGR Through 2034, Driven by Advances in Neurodegenerative Therapies | DelveInsight - PR Newswire","headline":"Alpha-synuclein Inhibitors Market to Witness Strong CAGR Through 2034, Driven by Advances in Neurodegenerative Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAJBVV95cUxPd3QyQ0JRbGF1TWJBNGZBTXJRWnV1a1hHVGgwcG5DUUFfMmZGYmlYQnpab3ZBVDhkQlU4cVpOdzZpcHd6NWFPbHhJMkkwcGtDbmQ3c0xUSk1kX055NXN1QzNvbzI3Um1BQ3U2WVlWWWtWUzRZWlBob09CdENuZm4zcGRQdThqbFRZNFNBeXBldVpNZTdWMl9tMmRiMHpHMFA4NnZWblRQTVJVMXhScjRjUXVuUmdBYjFBcDA3djNOaXJ5emNId29xN21VRE16SVk0RDhWcFNfR2NQV3pDUy1fLXBWLWZMRFYyOHYxYzJpa1VEWUtlRVpPNUdSRUxraUZESzhPWEZPdHVCNFRLVTdSbG9icUJaQWhyS050WjNzckRFaWpIYWF3cjVUWjQ4dkZUYTlCRlBadjNadHl4OXJtLXQ5dDJnVmc2?oc=5","date":"2025-07-08","type":"pipeline","source":"GlobeNewswire","summary":"Alzheimer’s Therapeutics Market on Upward Trajectory Across - GlobeNewswire","headline":"Alzheimer’s Therapeutics Market on Upward Trajectory Across","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxQMnZXNmsweU0zY1hhVk15eXRtZlAxWVhnQzA0SGVza1VHV3JVVzd3dHh6UWc0YU1tUjIxM0tLNDYxeHRvczdBR01zcmxpR25haGFaMTN6cS1kYzRHQ0Nyakw4X3NWVnBsZF9nNXFKN2NLM1g0MTdwWVFCMThLSVJOU21HV2hNWDRMS2g3RnJOblpTOTNHRU9DQkZtNnRoNEhiTElqaVFCZEhLVlFtS2ttdnM0dldaYmxuaUZyaGM3ektfSHdHal9aVkZhNmNSMzhORm9SMFVwMG1lMFhZRU1ZcWdpdlFObkdyYm84WDc0VjNJLWNtNE5qUGF3?oc=5","date":"2025-05-29","type":"regulatory","source":"PR Newswire","summary":"INBRIJA Positioned for Stronger Market Penetration as Demand Grows for Inhaled Parkinson's Therapy| DelveInsight - PR Newswire","headline":"INBRIJA Positioned for Stronger Market Penetration as Demand Grows for Inhaled Parkinson's Therapy| DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPcEZ3akphekFNenRhNHQ4LVJmWGVoaHRmRUlBYUVwb0VRSFBlQ2REa1JobGhaRGZYNmhKdDBueEdVUVQxTkhrSnRpNGtNbDdoVk1jTHJJSnFlVkZ6T2l3RGtsanpuVm5XWFNOQ250LWNDcGRPcmlZMWd5UW1WUHo5dzhJTnhBZnEtUHBaUEtJaXA2LWstc3ZZWUQ4LUtSRUxYQ01fN0xR?oc=5","date":"2024-12-10","type":"pipeline","source":"BioSpace","summary":"7 Most Promising Drugs in Parkinson’s Disease Treatment Pipeline - BioSpace","headline":"7 Most Promising Drugs in Parkinson’s Disease Treatment Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPdnVMTGt6WHhydGNISkIwSDVZekdtOVNwYU41RHMyQ1VZN0QxUDJRd1BzSnpiR1BXdGFWLWV4SjBzUjk0UVFLTUlObHY4d3BYcUhYb3VsTGhySFFoYU9UU0NhNTk4WUI0V21kZS0wdHJUMUVWcnpaeXJ2XzMtMHRsTW16dzRXYmswaER2Rk12a0pqZTlNc0V6SGJjSQ?oc=5","date":"2024-10-01","type":"pipeline","source":"Life Science Leader","summary":"Annovis Bio: Against The Grain In Alzheimer's Disease - Life Science Leader","headline":"Annovis Bio: Against The Grain In Alzheimer's Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPQzRCbWxiQk5qa1piSW1mYmNrUi1Yek9HMHhRTDNhZ1p0MmlTei1yLVFLUWtlZG56R2NiOUJrMmYwbDJhczF1VDhITXl2c2JkWkxnZWpPWFoyU2xLWjlnd2VoUkRYWk9DOGVUZFRWa2xwR1JYZlM5X1BjYXhiWU5tQUZWQU1wTzI4MWhxUzU1TVJSMFgybzRtRElTNVhZMVpCRExVV0xyaWdFbmgxY3AxVmpVaHpteHF3?oc=5","date":"2024-05-02","type":"trial","source":"seekingalpha.com","summary":"Impact Of Buntanetap Trial Results On Annovis Bio Stock And Future Prospects (NYSE:ANVS) - seekingalpha.com","headline":"Impact Of Buntanetap Trial Results On Annovis Bio Stock And Future Prospects (NYSE:ANVS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxOUnBSenQzUWtDWFlINnFDUEN3eEU4TzA1cnNVcnpwaFgzbjhhcTltSDVFekFUWXg1NW04LVptUEpWRUJLTk5LejN3WURCUTlHajZhTm9jclBFdGxwbTlGNEIyX2xVak1KQ21ET3Q4bE9JeFdtb3NrZkFsRHBnZUxFcy1HZTY?oc=5","date":"2024-02-23","type":"trial","source":"statnews.com","summary":"Annovis Bio delivers candor on its Parkinson’s study, even if it doesn’t inspire much confidence - statnews.com","headline":"Annovis Bio delivers candor on its Parkinson’s study, even if it doesn’t inspire much confidence","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}